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Abstract: It was previously observed that in a population of a high-income country, dietary multiple
micronutrient supplementation in pregnancy was associated with an increased risk of gestational
diabetes (GDM) and increased offspring size at birth. In this follow-up study, we investigated whether
similar changes are observed with dietary iron supplementation. For this we used the prospective
Cambridge Baby Growth Study with records of maternal GDM status, nutrient supplementation,
and extensive offspring birth size measurements. Maternal iron supplementation in pregnancy was
associated with GDM development (risk ratio 1.67 (1.01–2.77), p = 0.048, n = 677) as well as offspring
size and adiposity (n = 844–868) at birth in terms of weight (β’ = 0.078 (0.024–0.133); p = 0.005), head
circumference (β’ = 0.060 (0.012–0.107); p = 0.02), body mass index (β’ = 0.067 (0.014–0.119); p = 0.01),
and various skinfold thicknesses (β’ = 0.067–0.094; p = 0.03–0.003). In a subset of participants for
whom GDM statuses were available, all these associations were attenuated by adjusting for GDM. Iron
supplementation also attenuated the associations between multiple micronutrient supplementation
and these same measures. These results suggest that iron supplementation may mediate the effects
associated with multiple micronutrient supplementation in pregnancy in a high-income country,
possibly through the increased risk of developing GDM.
Keywords: fetal growth; gestational diabetes; development; adiposity; minerals; vitamins
1. Introduction
Although evidence from middle and low-income countries suggests that dietary sup-
plementation with multiple micronutrients in pregnancy is beneficial in terms of reducing
the prevalence of preterm births and low birth weight babies, as well as the numbers
born small for their gestational age (SGA) [1], its value in high-income countries is more
controversial. Our recent observational study of multiple micronutrient supplementation
in pregnancy also found positive associations even in a high-income country setting includ-
ing increased offspring weight, head circumference, and skinfold thicknesses at birth [2].
Multiple micronutrient supplementation was also associated with increased maternal ges-
tational diabetes (GDM) risk that may underpin the associations with increased offspring
size at birth. At present, it is not known which individual or group of micronutrients
caused the effects associated with multiple micronutrient supplementation in this study. It
does not appear to be folic acid supplementation, however, as our assessment of effects in
pregnancy produced results that failed to reflect those of supplementation with multiple
micronutrients [3]. Another candidate micronutrient for underpinning associations with
multiple micronutrient supplementation in pregnancy is iron.
Iron supplementation in pregnancy is common and indeed recommended in many
countries [4]. In the UK, however, it is only recommended for women who have iron
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deficiency or iron deficiency anaemia [5,6]. Most such supplementation in pregnancy is
therefore prophylactic and often taken with other vitamins and minerals in the form of
multiple micronutrient preparations. It has been assumed that for iron replete women
this is harmless [7] and that universal supplementation is beneficial in order to treat any
developing cryptic iron deficiency or iron deficiency anaemia. In recent years, however,
evidence has emerged of such dietary supplementation being associated with negative
consequences [8–13]. Thus, systematic reviews and meta-analyses have demonstrated that
both iron supplementation and having higher iron levels (either in the circulation or as
biomarkers of its storage) are associated with an increased threat of developing GDM [8–11]
and observational studies have demonstrated it to be associated with increased risk of
pre-eclampsia [12,13], possibly mediated through increased oxidative stress. Dietary iron
supplementation in pregnancy has also been reported to lead to increased offspring birth
weight [14] and it has been speculated that there may also be long-term consequences for
the children of pregnancies where iron was supplemented [15].
Following the previous studies linking dietary iron supplementation with GDM
development [8–11] and the recent observation of increased GDM risk in women supple-
menting their diets with (iron-containing) multiple micronutrients in pregnancy [2], we
hypothesised that iron supplementation in pregnancy mediated the previously observed
associations between multiple micronutrient supplementation in (1) pregnancy and GDM
risk and (2) offspring size at birth and adiposity. Furthermore, we postulated that we
would observe similar associations with iron supplementation to those that were observed
with multiple micronutrient supplementation [2]. We also assessed whether dietary iron
supplementation in pregnancy was associated with an increased risk of developing an
adverse hypertensive condition of pregnancy. We tested our hypothesis using a large
normal birth cohort where mothers were prospectively tracked through pregnancy until
the birth of their baby and detailed measures of the size at birth of the offspring were
recorded [16].
2. Materials and Methods
2.1. Cambridge Baby Growth Study
The prospective longitudinal Cambridge Baby Growth Study (CBGS) recruited women
from early pregnancy ultrasound clinics at the Rosie Maternity Hospital, Cambridge, UK,
to the first phase between 2001 and 2009 [16]. A total of 2229 pregnant women over the age
of 16 years were recruited to this part of the study, although 571 of them withdrew before
their baby was born and thus self-excluded. Women with multifetal pregnancies were
also excluded from the present analysis (due to the considerable effect on offspring birth
size [17]), as were women who did not fill in and return their pregnancy questionnaires.
The preponderance of the offspring in this cohort (95.3%) were White, with fewer offspring
being of mixed race (1.7%), Black African or Caribbean (1.3%), and Asian (1.7%).
Around week 28 of pregnancy, 1074 of the women underwent oral glucose tolerance
testing (OGTTs) using 75 g glucose loads consumed orally after overnight fasting [17]. The
results from the OGTTs were used to classify GDM using diagnostic criteria suggested by
the International Association of Diabetes in Pregnancy Study Group [18]. The prospective
data from this analysis was supplemented with blood pressure-related data collected
retrospectively to obtain as many useful records from individual pregnancies as possible.
Pre-eclampsia was classified from hospital notes using the terms “preeclampsia”, “pre-
eclampsia”, “pre-eclamptic toxaemia”, and “PET”. Gestational hypertension was classified
in 720 of all the women in the cohort using a combination of blood pressure measurements
taken after week 20 of pregnancy that were recorded from the hospital notes [19] and a
hospital diagnosis of “gestational hypertension”, “pregnancy-induced hypertension”, or
“PIH” [19]. Records of blood pressures in the other women were missing due to either
hospital notes not being available to us or those hospital notes not containing the relevant
results. Low birth weight was defined using the standard criterion of an unadjusted birth
weight of less than 2.5 kg. SGA was classified as a birth weight that was less than the
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10th percentile for gestational age when compared with UK growth charts. A birth was
described as premature if it occurred at less than 37 weeks gestation. The body mass index
(BMI) was calculated as the body weight (pre-pregnancy for the mother or at birth for
the baby) divided by the height or length squared. The ponderal index was calculated as
the BMI divided by the length. Pregnancy weight gain was determined as the pregnancy
weight (in the final week of pregnancy) minus the pre-pregnancy weight, both of which
were self-reported in the pregnancy questionnaire. The index of multiple deprivation was
collected from published tables derived using the participants’ residential postcodes [2].
2.2. Ethical Review
Ethical approval for the CBGS (00/325) was granted by the Cambridge Local Research
Ethics Committee, Addenbrooke’s Hospital, Cambridge, UK. Women gave informed
consent for both themselves and their babies. All procedures were followed according to
the institutional guidelines.
2.3. Assessment of Iron Supplementation in Pregnancy
At recruitment, an extensive questionnaire was given to each of the participants. They
were asked to complete it as the pregnancy progressed (with assistance from trained re-
search nurses if required) [2,17]. The questionnaires were collected post-partum. One of
the lifestyle questions asked included, “Have you taken any dietary supplements during
the pregnancy?” If this was answered “yes”, there was a table to fill in with “Name of
Product”, “Frequency”, and “Gestational Weeks” as column headings. Some of the rows of
the table were pre-filled to allow ticking; one of these was specifically for iron supplements.
Although 1239 of the CBGS participants filled in their pregnancy questionnaires, only
1001 participants gave unambiguous responses to the question about dietary supplemen-
tation and thus the remaining 238 participants were excluded from the present analysis.
Where a brand of dietary supplements was listed (rather than the specific variety of vita-
mins/minerals), an internet search was used to find whether the supplements included
iron [2]. Where a brand was listed without the name of the variety used, an assumption
was made that the supplement that was taken was that brand’s biggest-selling variety of
pregnancy supplement. Iron supplementation due to maternal anaemia as identified as
any disease indication was also self-reported. Multiple micronutrient supplementation
was categorised in the same manner as iron [2].
2.4. Assessment of Offspring Size at Birth
Birth weights were collected from hospital notes. Other new-born measurements were
made as close to birth as possible (at a median (interquartile range) of 2–16 days) by trained
paediatric nurses. These measurements included the baby’s length, head circumference,
and skinfold thickness at four sites. They were all measured in triplicates and the mean was
used in the analyses. Details of how the measurements were made have been presented
previously [2].
2.5. Assessment of the Potential Confounding Effects of Food Frequency Intakes on GDM Risk
A simple but validated food frequency questionnaire to be filled in as the pregnancy
progressed was also included in the full pregnancy questionnaire. Specific food intakes
were converted into a frequency of consumption score as previously described [17]. These
were then used to investigate if they confounded the link between iron supplementation in
pregnancy and increased GDM risk.
2.6. Statistical Analysis
This analysis follows a regrouping of data from pregnant women who were partic-
ipants in the CBGS that were included in the previous multiple micronutrient and folic
acid analyses [2,3]. The exposed group contained data from women who supplemented
their diets with iron alone, with iron and folic acid alone (or other single micronutrient),
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or with multiple micronutrients that included iron. The non-exposed group contained
data from women who supplemented their diets with micronutrients alone that did not
contain iron (e.g., folic acid, vitamin C, or vitamin D) or who did not supplement their
diets with micronutrients. Similar to the previous studies [2,3], it was analysed comparing
data from these two groups. Casewise deletion was generally used to address missing data
unless specified otherwise. Linear regression (adjusting for confounders where necessary)
was used to analyse continuous variables. If residuals were skewed, data transformation
(e.g., logarithmic adjustment) was applied prior to analysis. Logistic regression (reporting
relative risks (RR) via the use of log binominal regression), Fisher’s exact, and χ2-tests
were used to analyse categorical variables as appropriate. The statistical analyses were
conducted using Stata (version 13.1; Stata Corp., from Timberlake Consultants Ltd., Rich-
mond, Surrey, UK) or R (version 3.6.1; The R Foundation for Statistical Computing, Vienna,
Austria), and p < 0.05 was used to define statistical significance.
Sensitivity analyses were performed by repeating the association analyses in women
who supplemented their diets with iron alone (rather than via multiple micronutrient
supplementation) and by excluding those women who reported a diagnosis of anaemia
in pregnancy. Effects of potential mediators that may underpin the significant associa-
tions (GDM and weight gain in pregnancy) were tested in women for whom these data
were available by examining the effect of adjusting for those potential mediators on as-
sociations between iron supplementation and measures of size at birth. Similarly, iron
supplementation was tested as a mediator of the significant associations between (1) mul-




There were few clinical disparities between the women whose data was included in
this analysis and those that were excluded from it (Table S1). Those that were evident were
of the presence of a multifetal pregnancy (as data from these mothers were specifically
excluded from the analysis) and a lower proportion that smoked in a cohort where smoking
in pregnancy was relatively uncommon [16].
Most clinical characteristics did not differ between those women who took iron-
containing supplements in pregnancy (n = 582; 60.1%) and those that did not (n = 387;
39.9%) (Table 1). Of those that did, there was a slightly higher proportion of first pregnan-
cies in the women that supplemented their diets with iron. In addition, proportionally more
women (n = 524) amongst those that classified as taking iron took multiple micronutrient
supplements. In fact, as all the multiple micronutrient preparations used contained iron,
participants who supplemented with multiple micronutrients were all classified as taking
iron (apart from those that were excluded from the whole analysis due to having multifetal
pregnancies). All the multiple micronutrient preparations also contained folic acid, sup-
ported by the fact that there was a higher proportion of those that took iron supplements
than those that did not also supplement with folic acid. All but one of the women who
reported experiencing anaemia during pregnancy (n = 27) took iron supplements (as single
supplements; the one participant with anaemia who did not use iron supplements took
folic acid). Although there were a wide range of start times, the modal time of when
women started supplementing with iron was around conception (Figure S1) and many of
the women continued supplementing throughout pregnancy.
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Table 1. A comparison of the characteristics of those CBGS maternal participants who supplemented their diets with iron
during pregnancy and those that did not.
Maternal Characteristic No Iron Supplementation(n = 252–387)
Iron Supplementation
(n = 377–582) p-Value
Age (years) 33.2 (32.8–33.6) 33.6 (33.3–34.0) 0.1
Height (m) 1.66 (1.65–1.66) 1.66 (1.66–1.67) 0.2
Pre-pregnancy weight (kg) 66.3 (64.9–67.6) 66.2 (65.0–67.3) 0.9
Pre-pregnancy BMI (kg/m2) 24.2 (23.7–24.7) 24.0 (23.6–24.3) 0.5
Weight gain in pregnancy (kg) 7.8 (7.0–8.7) 8.9 (8.2–9.5) 0.05
Index of multiple deprivation 8.7 (8.2–9.2) 8.7 (8.3–9.1) 0.9
First pregnancy (n yes, n no) 148 yes, 238 no 277 yes, 304 no 0.03
Smoked during pregnancy (n) 14 yes, 372 no 17 yes, 564 no 0.5
Anaemia (n) 1 yes, 366 no 26 yes, 540 no 2.8 × 10−5
Supplemented with multiple
(3 or more) micronutrients in
pregnancy (n)
8 yes, 378 no 516 yes, 59 no 1.1 × 10−157
Supplemented with folic acid
in pregnancy (n) 204 yes, 183 no 567 yes, 10 no 3.0 × 10
−67
Length of pregnancy (weeks) 39.8 (39.6–40.0) 39.9 (39.8–40.1) 0.2
Birth presentation (n head, n
breach, and n other) 304 head, 16 breach, and 30 other 433 head, 20 breach, and 51 other 0.7
Delivery (n vaginal, n vacuum,
n forceps, n elective section,
and n acute section)
231 vaginal, 20 vacuum,
16 forceps, 61 elective section, and
55 acute section
333 vaginal, 40 vacuum,
31 forceps, 78 elective section,
and 84 acute section
0.6
Data are mean (95% confidence interval) or number of participants. p-values were gained using linear regression, χ2-test, or Fisher’s exact
tests as appropriate.
3.2. Associations with Adverse Outcomes of Pregnancy and Offspring Size at Birth
A higher proportion of women who took iron supplements developed GDM than
the proportion of those that did not (RR 1.67 (1.01–2.77); n = 677; p = 0.048; Table 2). This
raised RR was only partially attenuated by adjusting for various food frequency intakes
(Table S2). There was a borderline increase in weight gain in those women who supple-
mented their diets with iron (p = 0.05). There were no differences between iron supplemen-
tation groups in the proportion of women that developed either gestational hypertension
or pre-eclampsia, or in the proportion that gave birth to premature, SGA, or low birth
weight babies.
Table 2. Numbers and relative risks of various adverse conditions of pregnancy according to whether or not the participants
supplemented their diets with iron.
Condition No IronSupplementation Iron Supplementation Relative Risk p-Value
Gestational diabetes (n yes, n no) 19 yes, 247 no 49 yes, 362 no 1.669(1.006–2.770) 0.048
Pre-eclampsia (n yes, n no) 7 yes, 385 no 8 yes, 585 no 0.755(0.276–2.067) 0.6
Gestational hypertension (n yes,
n no) 11 yes, 175 no 16 yes, 272 no 0.939(0.446–1.979) 0.9
Low birth weight (n yes, n no) 12 yes, 373 no 15 yes, 566 no 0.828(0.392–1.750) 0.6
Small for gestational age (n yes,
n no) 2 yes, 383 no 3 yes, 578 no 0.994 (0.167–5.921) 1.0
Premature birth (n yes, n no) 7 yes, 379 no 11 yes, 571 no 1.042 (0.408–2.665) 0.9
Data are number of participants or mean (95% confidence interval). p-values were gained using logistic regression.
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Maternal iron supplementation in pregnancy was associated with increased offspring
weight (p = 0.005), head circumference (p = 0.02), BMI (p = 0.01), and skinfold thicknesses
in three of the four sites (p = 0.03–0.003) (the fourth having a borderline significance of
p = 0.05) (Table 3). In the participants who supplemented with iron that was not part
of a multiple micronutrient preparation (n = 60–63, around 12% of the total number of
participants that supplemented their diets with iron), the maternal iron supplementation
was still associated with increased offspring subscapular skinfold thicknesses (p = 0.03;
Table S3).
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(n = 513) 0.094 (0.033–0.156) 0.003
Standardised βs are shown as mean (95% confidence interval). p-values were gained using multiple linear regression models. All models
were adjusted for gestational age at birth, parity (as a continuous variable), smoking during pregnancy, offspring sex, and maternal
pre-pregnancy BMI. * Models additionally adjusted for age at assessment.
3.3. Exploration of Potential Effects Related to Anaemia, GDM, and Pregnancy Weight Gain
Excluding women who reported being anaemic during pregnancy, associations per-
sisted between maternal iron supplementation in pregnancy and both the development of
GDM (RR 1.70 (1.01–2.86); p = 0.045) and offspring size at birth (Table S4). In 663 women
for whom GDM statuses were available and who were included in both the multiple
micronutrient and iron supplementation analyses, as expected, multiple micronutrient
supplementation was associated with GDM (RR 1.87 (1.13–3.08); p = 0.02). When adjusted
for iron supplementation, the significance of the association with multiple micronutrient
supplementation in the same women was lost (RR 1.76 (0.64–4.81); p = 0.3). Adjusting for
iron supplementation also attenuated associations between dietary supplementation with
multiple micronutrients and offspring size at birth (Table 4).
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Table 4. Subgroup comparison assessing the confounding effect of iron supplementation on the associations between






Adjusted for Iron Supplementation
Standardised β p-Value Standardised β p-Value
Weight 849 0.063 (0.008–0.118) 0.03 −0.036 (−0.142–0.070) 0.5
Length * 827 0.034 (−0.015–0.084) 0.2 −0.027 (−0.122–0.068) 0.6
Head circumference * 828 0.052 (0.003–0.101) 0.04 0.001 (−0.094–0.095) 1.0
BMI * 825 0.049 (−0.005–0.103) 0.08 −0.042 (−0.146–0.062) 0.4
Ponderal index * 825 0.036 (−0.016–0.088) 0.2 −0.025 (−0.125–0.076) 0.6
Flank skinfold
thickness * 827 0.065 (0.003–0.127) 0.04 0.021 (−0.098–0.141) 0.7
Quadriceps skinfold
thickness * 827 0.061 (0.007–0.115) 0.03 0.052 (−0.052–0.157) 0.3
Subscapular skinfold
thickness * 827 0.070 (0.009–0.130) 0.03 −0.027 (−0.144–0.090) 0.7
Triceps skinfold
thickness * 827 0.096 (0.034–0.159) 0.003 0.042 (−0.078–0.163) 0.5
Values in the table only include data from those pregnancies where the mothers were part of both the multiple micronutrient and iron
studies. Standardised βs are shown as mean (95% confidence interval). p-values were gained using multiple linear regression models. All
models were adjusted for gestational age at birth, parity (as a continuous variable), smoking during pregnancy, offspring sex, and maternal
pre-pregnancy BMI. * Models additionally adjusted for age at assessment.
In 608 women for whom relevant data were available, adjusting for GDM attenuated
the various associations between maternal iron supplementation in pregnancy and off-
spring size at birth (Table S5). A smaller effect was noted in 632 women with relevant data
when adjusting the statistical models for pregnancy weight gain (Table S6).
4. Discussion
In this analysis, women who supplemented their diets with iron in pregnancy had an
increased risk of developing GDM as well as increases in various measures of offspring
size at birth (including their weight, head circumference, BMI, and skinfold thicknesses).
These findings are very similar to previously observed associations with pregnant women
who supplemented their diets with multiple micronutrients [2]. Unlike with the lack of
effects associated with folic acid supplementation in pregnancy [3], these results suggest
that the multiple micronutrient supplementation associations may have been mediated
at least in part by iron supplementation. In the UK, iron supplementation is not routinely
recommended for pregnant women until after either iron deficiency or iron deficiency
anaemia has been diagnosed [20]. However, in the CBGS it was common to supplement
maternal diets with iron, most often in the form of multivitamin and mineral tablets (90.6%
of those that supplemented their diets with iron). The format used in this study results
in a difficulty to differentiate the effects of multiple micronutrient supplementation from
those of iron supplementation as all the multiple micronutrient preparations contained
iron. The main difference from the multiple micronutrient study [2] relates to the data
collected from the women who supplemented their diets with iron but did not take multiple
micronutrients. These would have been considered non-exposed in the previous study [2];
thus, in comparing results from both studies, the key associations from the original study
would have been expected to be somewhat attenuated by their inclusion in the exposed
group if iron were not involved in mediating them. This was not what was observed,
however. In addition, when assessing associations with offspring size at birth in the small
subset of women who supplemented their diets with iron alone (along with non-exposed
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participants), the vast majority of the associations were in the same direction as those in
the full study, albeit mainly non-significantly probably due to the reduction in statistical
power. The association with offspring subscapular skinfold thicknesses with maternal iron
supplementation in pregnancy was still significant, however. These results are therefore
consistent with a role for maternal iron supplementation in mediating the main associations
from the present study. In support of this are findings from clinical trials where iron was
supplemented in isolation [21,22]. Consistent with a role for iron in mediating the multiple
micronutrient associations, in the present analysis iron supplementation attenuated previ-
ously observed associations between multiple micronutrient supplementation and both
the maternal risk of developing GDM and increases in offspring birth size [2].
In addition to results suggesting that iron supplementation may have mediated
previously observed associations with multiple micronutrient supplementation [2], this
analysis confirmed previous studies that found associations between iron supplementation
in pregnancy and an increased risk of the development of GDM [8–11] (by around 70%
in the present analysis). It also confirmed previous observations linking maternal iron
supplementation in pregnancy with increased offspring birth weight [14], extending this
finding to positive associations with various other measures of offspring size at birth such as
BMI and three of the four skinfold measurements that were assessed (the other one reaching
borderline significance in the same direction). This suggests that iron supplementation in
pregnancy is associated with increased offspring adiposity at birth. Adiposity is thought
to be better estimated by ponderal index than BMI at birth [23] but the association with
ponderal index in the present analysis was in the same direction as that of BMI even if
statistical significance was not reached. We did not find an effect on length at birth which is
consistent with a meta-analysis of randomised trials and cohort studies regarding the effect
of iron supplementation in pregnancy [24]. Neither could we find links between adverse
pregnancy outcomes such as premature birth, pre-eclampsia and gestational hypertension,
and maternal dietary iron supplementation in pregnancy. However, these analyses could
have been somewhat underpowered in the CBGS population where these adverse outcomes
appeared to occur less frequently than GDM. The lack of association between maternal iron
supplementation in pregnancy and maternal adverse hypertensive pregnancy outcomes
does not indicate that there will not be long-term changes in the blood pressure of the
offspring [25].
We found that GDM attenuated all the associations between iron supplementation in
pregnancy and the various measures of size at birth. These assessments were conducted at a
time when there was a temporal trend for a rising prevalence of GDM in this population [26],
although the relationship between iron supplementation in pregnancy and the development
of GDM was not so strong that there was a concurrent temporal trend in dietary iron
supplementation (data not shown). The results from the present study suggest that GDM
may mediate at least part of the link between maternal dietary iron supplementation in
pregnancy and increased offspring adiposity and size at birth. Consistent with this, CBGS
participants who developed GDM tended to give birth to heavier babies [27]. It has been
suggested that adverse outcomes of pregnancy may be linked to iron supplementation
through increases in oxidative stress [28]. In reviewing the links between iron status,
oxidative stress, and GDM, Zein et al. [29] suggested a mechanism whereby dietary iron
supplementation may initially lead to a state of increased oxidative stress (GDM being of
such a state [29,30]). This increased oxidative stress may then enhance insulin resistance
(possibly resulting from a reduced ability of the liver to extract insulin). The increased
oxidative stress may also even lead to pancreatic β-cell dysfunction. The combination of
the enhanced insulin resistance and the pancreatic β-cell dysfunction in turn may then
contribute to the development of GDM [29].
The strengths of this study include the levels of detail available to us in relation to
the assessment of size at birth and maternal GDM status in a relatively large number of
newborns and women that were part of a well-characterised cohort. It also has a number
of limitations, however. Firstly and most importantly, we analysed iron supplementation
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in pregnancy only as a dichotomous exposure; thus, there was no account of the stage of
pregnancy when iron was supplemented, the doses of iron consumed, the dietary iron
consumption, or maternal iron status. However, this approach had the advantage of
increasing the numbers of participants available to us due to fewer exclusions resulting
from missing iron-related data. Also, it has been shown by meta-analysis that the duration
of iron use in pregnancy is not significantly associated with outcomes such as increases in
birth weight [24]. A second limitation is that data relating to iron supplementation and
anaemia were self-reported that could have introduced inaccuracies [31]. However, the
questionnaire that we used was based on one that was validated by phone interviews [32]
that may have limited inaccuracies. The overall extent to which data were missing is a
further weakness. However, this is common in cohort studies that are used for multiple
analyses. While missing data could have been imputed in the present analysis, this
might have increased measurement errors and introduced inaccurate confidence interval
estimates. Instead, casewise deletion of missing data was generally used.
In conclusion, this analysis confirmed previous reported associations between iron
supplementation in pregnancy and both maternal GDM and increased offspring birth
weight. We extended this to other measures of size at birth and demonstrated that
the principal reason for the increased weight seems to be increased adiposity. These
associations appeared to be mediated by the increased risk of GDM. The main associa-
tions with iron supplementation reflected and attenuated those with multiple micronu-
trient supplementation in this cohort, suggesting that it may be the main mediator of
such associations.
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that these women supplemented with iron; Table S1: comparison of characteristics of those that
were included in this present analysis and those that were excluded from it; Table S2: effect of
including specific food frequency intakes as confounders in the logistic regression models describing
the relationship between iron supplementation during pregnancy and risk of GDM in the Cambridge
Baby Growth Study; Table S3: associations between iron supplementation status in pregnancy and
indices of offspring size at birth; Table S4: associations of iron supplementation in pregnancy with
(a) outcomes of pregnancy and (b) offspring size at birth and adiposity in women and babies
in absence of reported maternal anaemia; Table S5: subgroup comparison assessing the effect of
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birth; and Table S6: subgroup comparison assessing the effect of maternal weight gain in pregnancy
on associations between iron supplementation in pregnancy and offspring size at birth.
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